Navigation Links
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Date:12/16/2009

pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA (including ODAC), CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.



    Media Contact:                        Investors Contact:
    Dan Eramian                           Ed Bell
    T: 206.272.4343                       T: 206.272.4345
    C: 206.854.1200                       Lindsey Jesch Logan
    F: 206.272.4434                       T: 206.272.4347
    E: deramian@ctiseattle.com            F: 206.272.4434
    www.celltherapeutics.com/press_room   E: invest@ctiseattle.com
                                          www.celltherapeutics.com/investors


SOURCE Cell Therapeutics, Inc.'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... 8, 2011 Elsevier Business Intelligence , ... conferences, is hosting Windhover,s 21 st Pharmaceutical Strategic ... in New York, NY. PSA is the only ... a diverse mix of pharma,s top talent. It,s an opportunity ...
... Medical, a leading manufacturer of integrated medical imaging display and ... year, Carrot Medical achieved significant growth in sales and an ... of 2011 with record second quarter sales, Carrot surpassed its ... company is now well positioned for the third straight year ...
Cached Medicine Technology:Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 2Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 3Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2
(Date:8/31/2015)... ... 31, 2015 , ... Garden State Urology is celebrating seven ... a merger of five of the busiest urology practices in Morris County. They ... and higher quality care than they did individually. Their mission statement reflects ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... Since ... quality, patient-oriented dental care. From the moment a patient arrives at the office, ... Steven Tuckman will work with each and every patient to create a complete dental ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports ... Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
(Date:8/31/2015)... ... ... According to an article published August 3rd on Healio, a ... bariatric surgery “felt significantly better two years after surgery.” The article goes on to ... felt that their “mental health had been normalized” at the point when the follow-up ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3
... CPR training available to healthcare professionalsDALLAS and CLIFTON ... provider of e-Learning solutions for healthcare training and ... offer a portion of initial or renewal certification ... (BLS) online via NetLearning,s Learning Management Systems. ...
... Congress and states reconsider funding for abstinence-only programs, the ... education classes reveals that abstinence programs are plagued with ... sexuality and actively discourage the use of condoms to ... the Texas Freedom Network Education Fund - Just ...
... Teva Pharmaceuticals USA, the leading generic pharmaceutical ... of videos as part of the "Year of ... (available at www.yearofaffordablehealth.com/gallery ) is meant to ... for everyday Americans since the passage of Waxman-Hatch ...
... of MGT Capital Investments, Inc. (NYSE AMEX US: MGT), ... that focuses on products, software and equipment used by ... review of the selected products each month. A ... upcoming months is available at http://www.medicexchange.com/medicexchange-product-reviews.html . , ...
... a successful showing at the 2009,South Beach Food and ... hit over 300 stores in South Florida since the ... opened accounts include: CVS on Lincoln Road,Miami Beach; Walgreens, ... Markets, Tom Thumb, Penn Dutch, Quick Stop, Shell Gas ...
... Hematology Results Are InMUNDELEIN, Ill., Feb. 24 ... manufacturer and laboratory information systems developer today announced ... in industry for instrument reliability for its ninth ... In this annual report, Sysmex also ranked ...
Cached Medicine News:Health News:NetLearning to Offer American Heart Association e-Learning Courses 2Health News:New Texas Study Reveals Serious Flaws in Abstinence Programs 2Health News:MedicExchange Announces Launch of 'Radiology Product Review' Program 2Health News:MedicExchange Announces Launch of 'Radiology Product Review' Program 3Health News:Next Generation Waters Successfully Reaches Over 300 Stores! 2Health News:Sysmex Customer Satisfaction Ranks Highest in Independent Market Research 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: